Temporal and age distributions of SARS-CoV-2 and other coronaviruses, southeastern France

Colson, Philippe; Esteves-Vieira, Véra; Giraud-Gatineau, Audrey; Zandotti, Christine; Filosa, Véronique; Chaudet, Hervé; Lagier, Jean-Christophe; Raoult, Didier

doi:10.1016/j.ijid.2020.09.1417

Cited by 8 publications

(11 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In IHU in Marseille, France, we have carried out SARS-CoV-2 RNA testing using real-time reverse transcription-PCR (qPCR) since the end of January 2020, as previously described [ 1 , 5 ]. The numbers of tests and cases were daily monitored since the first positive diagnosis on 02/27/2020 [ 2 ] ( https://www.mediterranee-infection.com/covid-19/ ).…”

Section: Methodsmentioning

confidence: 99%

“…The SARS-CoV-2 virus emerged in humans in Wuhan, China, in December 2019, prior to speading worldwide. In China and Europe, the epidemic had a bell shape typical of a respiratory virus ( https://covid19-country-overviews.ecdc.europa.eu/ ) [ 1 , 2 ]. Surprisingly, in the countries that closed their borders, the evolution varied: in some countries, no other epidemic was detected whereas in others, new epidemic waves occurred, caused by new variants [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: An investigational study

Colson

Levasseur

Fénollar

et al. 2021

Travel Medicine and Infectious Disease

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: An investigational study

Colson

Levasseur

Fénollar

et al. 2021

Travel Medicine and Infectious Disease

Self Cite

View full text Add to dashboard Cite

“…The SARS-CoV-2 epidemic exhibited a bell-shaped incidence curve [24] (https:// www.newsbeast.gr/files/1/2020/05/COVID19PredictionPaper. pdf) (https://coronavirus.jhu.edu/data/new-cases; https:// www.mediterranee-infection.com/covid-19/; Figure 2), which is a typical epidemic curve [25]. In Western countries, in the Northern hemisphere, the outbreak decreased dramatically during the spring, as is the case for epidemics arising from other respiratory viruses.…”

Section: Sars-cov-2 Epidemiologymentioning

confidence: 95%

“…Moreover, SARS-CoV-2 affected people differently according to their age. Very few cases and less severe outcomes were observed in children [25][26][27][28][29][30][31][32][33], while SARS-CoV-2 infections have been more prevalent and severe in the elderly. For instance, a large study conducted in Iceland on the general population reported that children under the age of 10 were half as likely to be diagnosed with SARS-CoV-2 than children over the age of 10 or adults [32].…”

Section: Sars-cov-2 Epidemiologymentioning

confidence: 99%

Natural history of COVID-19 and therapeutic options

Gautret

Million

Jarrot

et al. 2020

Expert Review of Clinical Immunology

Self Cite

121

109

View full text Add to dashboard Cite

Introduction: COVID-19 presents benign forms in young patients who frequently present with anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of age with comorbidities, including hypertension and diabetes. Lymphopenia, eosinopenia, thrombopenia, increased lactate dehydrogenase, troponin, C-reactive protein, D-dimers and low zinc levels are associated with severity.Areas covered: The authors review the literature and provide an overview of the current state of knowledge regarding the natural history of and therapeutic options for COVID-19. Expert opinion: Diagnosis should rely on PCR and not on clinical presumption. Because of discrepancies between clinical symptoms, oxygen saturation or radiological signs on CT scans, pulse oximetry, and radiological investigation should be systematic. The disease evolves in successive phases: an acute virological phase, and, in some patients, a cytokine storm phase; an uncontrolled coagulopathy; and an acute respiratory distress syndrome. Therapeutic options include antivirals, oxygen therapy, immunomodulators, anticoagulants and prolonged mechanical treatment. Early diagnosis, care, and implementation of an antiviral treatment; the use of immunomodulators at a later stage; and the quality of intensive care are critical regarding mortality rates. The higher mortality observed in Western countries remains unexplained. Pulmonary fibrosis may occur in some patients. Its future is unpredictable.

show abstract

“…The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic that started in Wuhan, China in December 2019 has spread rapidly around the world (https://coronavirus.jhu.edu/ map.html). At the Méditerranée Infection Institute (IHU) in Marseille, routine diagnosis of SARS-CoV-2 by PCR was set up in January 2020 (Lagier et al, 2020;Colson et al, 2020a). The first SARS-CoV-2-infected patient was diagnosed at the IHU on February 27, 2020 (Colson et al, 2020c) (https://www.mediterranee-infection.com/covid-19/).…”

Section: Introductionmentioning

confidence: 99%

Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’ variant

Fournier

Colson

Levasseur

et al. 2021

International Journal of Infectious Diseases

Self Cite

View full text Add to dashboard Cite

Introduction In Marseille, France, following a first SARS-CoV-2 outbreak in March-May 2020, a second epidemic phase occurred from June, involving ten new variants. The Marseille-4 variant caused an epidemic that started in August and is still ongoing. Materials and methods The 1,038 SARS-CoV-2 whole genome sequences obtained in our laboratory by next-generation sequencing with Illumina technology were analyzed using Nextclade and nextstrain/ncov pipelines and IQ-TREE. A Marseille-4-specific qPCR assay was implemented. Demographic and clinical features were compared between patients with Marseille-4 and earlier strains. Results Marseille-4 harbors 13 hallmark mutations. One leads to S477 N substitution in the spike receptor binding domain targeted by current vaccines. Using a specific qPCR, we observed that Marseille-4 caused 12-100% of SARS-CoV-2 infections in Marseille from September 2020, being involved in 2,106 diagnoses. This variant was more frequently associated with hypoxemia than clade 20A strains before May 2020. It caused re-infection in eleven patients SARS-CoV-2-diagnosed with different strains before June 2020, suggesting either short-term protective immunity or lack of cross-immunity. Discussion/conclusion Marseille-4 should be considered as a major SARS-CoV-2 variant. Its sudden appearance points toward an animal reservoir, possibly minks. The protective role of past-exposure and current vaccines against this variant should be evaluated.

show abstract

Temporal and age distributions of SARS-CoV-2 and other coronaviruses, southeastern France

Cited by 8 publications

References 11 publications

Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: An investigational study

Introduction into the Marseille geographical area of a mild SARS-CoV-2 variant originating from sub-Saharan Africa: An investigational study

Natural history of COVID-19 and therapeutic options

Emergence and outcomes of the SARS-CoV-2 ‘Marseille-4’ variant

Contact Info

Product

Resources

About